<html>
<head><title>
Prepared and filed by St Ives Financial
</title>
</head>
<body bgcolor="#FFFFFF">
<page>
<p align="center">&nbsp;</p>
<p align="center"><font size="2" face="serif">SECURITIES AND EXCHANGE COMMISSION<br>
  WASHINGTON, D.C. 20549</font></p>
<p align="center"><font size="2" face="serif">_______________________</font></p>
<p align="center"><font size="2" face="serif">FORM 8-K</font></p>
<p align="center"><font size="2" face="serif">CURRENT REPORT<br>PURSUANT TO SECTION 13 OR 15(d) OF<br>THE SECURITIES EXCHANGE ACT OF 1934</font></p>
<p align="center"><font size="2" face="serif">Date of Report (Date of earliest event reported):  April 5, 2006</font></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td align="center"><font size="2" face="serif">Savient Pharmaceuticals, Inc.</font> </td>
  </tr>
  <tr>
    <td align="center"><hr size="1" noshade></td>
  </tr>
  <tr>
    <td align="center"><font size="2" face="serif">(Exact name of registrant
    as specified in charter)</font></td>
  </tr>
</table>
<p align="center">&nbsp;</p>
<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr align="center" valign="top" bgcolor="#ffffff">
<td><font size="2" face="serif">Delaware</font></td>
<td width="30%"><font size="2" face="serif">0-15313                </font></td>
<td width="30%"><font size="2" face="serif">13-3033811</font></td>
</tr>
<tr align="center" valign="top" bgcolor="#FFFFFF">
  <td><hr size="1" noshade></td>
  <td><hr size="1" noshade></td>
  <td><hr size="1" noshade></td>
</tr>
<tr align="center" valign="top" bgcolor="#FFFFFF">
<td><font size="2" face="serif">(State or other juris-<br>
  diction of incorporation</font></td>
<td><font size="2" face="serif">(Commission<br>
  File Number)</font></td>
<td><font size="2" face="serif">(IRS Employer<br>
  Identification No.)</font></td>
</tr>
</table>
<br><br>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td align="center"><font size="2" face="serif">One Tower Center, 14th Floor</font><br><font size="2" face="serif">East Brunswick, New Jersey 08816</font></td>
</tr>
<tr valign="top">
  <td align="center"><hr size="1" noshade></td>
</tr>
<tr valign="top">
<td align="center"><font size="2" face="serif">(Address of principal executive offices) (Zip Code)</font></td>
</tr>
</table>
<p align="center"><font size="2" face="serif">Registrant&#8217;s telephone number, including area code:  (732) 418-9300</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td align="center"><font size="2" face="serif">Not applicable</font></td>
</tr>
<tr valign="top">
  <td align="center"><hr size="1" noshade></td>
</tr>
<tr valign="top">
<td align="center"><font size="2" face="serif">(Former name or former address, if changed since last report)</font></td>
</tr>
</table>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;<img src="emptybox.gif" width="12" height="12"></font></td>
<td align="left"><font size="2" face="serif">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;<img src="emptybox.gif" width="12" height="12"></font></td>
<td align="left"><font size="2" face="serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;<img src="emptybox.gif" width="12" height="12"></font></td>
<td align="left"><font size="2" face="serif">Pre-commeYncement communications
    pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2{b))</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;<img src="emptybox.gif" width="12" height="12"></font></td>
<td align="left"><font size="2" face="serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td>
</tr>
</table>
<p>&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page> <a name="p?"></a>
<p align="center">&nbsp;</p>
<p align="left"><font size="2" face="serif"><b>Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.</b></font></p>
<p align="left"><font size="2" face="serif" align="left">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Effective as of April 5, 2006, Carl E. Kaplan has retired from his position as a member of the Board of Directors of Savient Pharmaceuticals, Inc.  Mr. Kaplan&#8217;s letter of retirement is set forth in exhibit 17.1.</font></p>
<p align="left"><font size="2" face="serif"><b>Item 9.01.  Financial Statements
      and Exhibits.</b></font></p>
<p align="left"><font size="2" face="serif" align="left">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exhibits</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See Exhibit Index attached hereto.</font></p>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<a name="p?"></a>
<p>&nbsp;</p>
<p align="center"><font size="2" face="serif">SIGNATURE</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td width="50%">&nbsp;</td>
    <td colspan="2"><font size="2" face="serif">SAVIENT PHARMACEUTICALS, INC.</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td width="5%">&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="2" face="serif">Date: April 10, 2006</font></td>
    <td><font size="2" face="serif">By:</font></td>
    <td><font size="2" face="serif">/s/ Philip K. Yachmetz</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><hr size="1" noshade></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font size="2" face="serif">Philip K. Yachmetz<br>
      Executive Vice President &amp; <br>
    Chief Business Officer</font></td>
  </tr>
</table>
<p align="left">&nbsp;</p>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<a name="p?"></a>
<p>&nbsp;</p>
<p align="center"><font size="2" face="serif">EXHIBIT INDEX</font></p>
<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top" bgcolor="#FFFFFF">
<td width="10%" align="left"><font size="2" face="serif"><u>Exhibit No.</u></font></td>
<td width="59%" align="left"><font size="2" face="serif"><u>Description</u></font></td>
<td width="2%" align="left">&nbsp;</td> </tr>
<tr valign="top">
<td></td>
<td>&nbsp;</td>
<td></td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="left"><font size="2" face="serif">17.1</font></td>
<td align="left"><font size="2" face="serif">Letter of Retirement from Carl E. Kaplan, dated April 5, 2006.&nbsp;</font></td>
<td align="left">&nbsp;</td>
</tr>
</table>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "b412677_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 8140}]
{"company-data": {"conformed-name": "SAVIENT PHARMACEUTICALS INC", "cik": "0000722104", "assigned-sic": "2833", "irs-number": "133033811", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-15313", "film-number": "06751432"}, "business-address": {"street1": "ONE TOWER CENTER", "city": "EAST BRUNSWICK", "state": "NJ", "zip": "08816", "phone": "7324189300"}, "mail-address": {"street1": "ONE TOWER CENTER", "city": "EAST BRUNSWICK", "state": "NJ", "zip": "08816"}, "former-company": {"former-conformed-name": "BIO TECHNOLOGY GENERAL CORP", "date-changed": "19920703"}}
Prepared and filed by St Ives Financial
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):  April 5, 2006
Savient Pharmaceuticals, Inc.
(Exact name of registrant
    as specified in charter)
Delaware
0-15313
13-3033811
(State or other juris-
diction of incorporation
(Commission
File Number)
(IRS Employer
Identification No.)
One Tower Center, 14th Floor
East Brunswick, New Jersey 08816
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code:  (732) 418-9300
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commeYncement communications
    pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2{b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
(b)      Effective as of April 5, 2006, Carl E. Kaplan has retired from his position as a member of the Board of Directors of Savient Pharmaceuticals, Inc.  Mr. Kaplan's letter of retirement is set forth in exhibit 17.1.
Item 9.01.  Financial Statements
      and Exhibits.
(d)      Exhibits
See Exhibit Index attached hereto.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SAVIENT PHARMACEUTICALS, INC.
Date: April 10, 2006
By:
/s/ Philip K. Yachmetz
Philip K. Yachmetz
Executive Vice President &
Chief Business Officer
EXHIBIT INDEX
Exhibit No.
Description
17.1
Letter of Retirement from Carl E. Kaplan, dated April 5, 2006.